BPC-157 + TB-500 Blend
Stable gastric pentadecapeptide (BPC-157) + N-terminal thymosin-β4 fragment (TB-500) blend
- Class
- Healing peptide blend
- Half-life
- BPC ~4h · TB ~24h
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Animal data primarily
Overview
The canonical 'healing stack' research-peptide vendors offer pre-mixed. BPC-157 and TB-500 hit completely different repair mechanisms — BPC-157 drives angiogenesis and gut-mucosal healing via the VEGFR2 / NO pathway; TB-500 sequesters G-actin and accelerates cell migration / wound-edge advancement via thymosin-β4 biology. Combining them is the pharma logic of attacking tissue repair from two non-overlapping angles.
Where the evidence stands: both components are heavily animal-evidenced (BPC-157 has ~150 rodent papers; TB-500/Tβ4 has cardiac, dermal, and ophthalmic preclinical work). Human RCT data for either individually is thin and for the BLEND specifically is almost zero — most user reports come from forums (Reddit r/Peptides, MESO-Rx, athletes) rather than trials. Read this page as 'here's the pharmacology + what users describe', not 'here's what trials proved'.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved for human use anywhere. Research-market product with variable purity.
- WADA prohibited — TB-500 is explicitly on the prohibited list; BPC-157 is likely covered under 'similar substances'. Hard no for tested athletes.
- Theoretical concern: both peptides promote angiogenesis. Avoid in active or recent cancer (angiogenesis = tumour growth fuel).
+ 2 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching BPC-157 + TB-500 Blend.
- Subjective recovery markers — soreness duration, sleep quality, injury-site pain
- Injury-specific imaging (MRI/ultrasound) if you're treating a known structural injury
- Blood pressure (BPC-157 has mild BP-lowering effect in rodents)
- Injection-site reactions (more common with TB-500 than BPC)
- WADA status — both are prohibited for tested athletes
Frequently asked questions
What is BPC-157 + TB-500 Blend?
Stable gastric pentadecapeptide (BPC-157) + N-terminal thymosin-β4 fragment (TB-500) blend. The canonical 'healing stack' research-peptide vendors offer pre-mixed. BPC-157 and TB-500 hit completely different repair mechanisms — BPC-157 drives angiogenesis and gut-mucosal healing via the VEGFR2 / NO pathway; TB-500 sequesters G-actin and accelerates cell migration / wound-edge advancement via thymosin-β4 biology. Combining them is the pharma logic of attacking tissue repair from two non-overlapping angles.
How is BPC-157 + TB-500 Blend administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of BPC-157 + TB-500 Blend?
BPC ~4h · TB ~24h — BPC-157 sc ~4 h. TB-500 sc ~24 h — much longer hang-time. The TB half drives the dosing schedule (2-3×/week typical)..
Is BPC-157 + TB-500 Blend approved for human use?
BPC-157 + TB-500 Blend is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for BPC-157 + TB-500 Blend?
Evidence tier: Animal data primarily. Most user reports come from injury-recovery contexts — tendon sprains, post-surgical, chronic gut issues. The 'maintenance / longevity' use case has even thinner evidence.
What is commonly monitored when researching BPC-157 + TB-500 Blend?
Commonly tracked markers + signals: Subjective recovery markers — soreness duration, sleep quality, injury-site pain, Injury-specific imaging (MRI/ultrasound) if you're treating a known structural injury, Blood pressure (BPC-157 has mild BP-lowering effect in rodents), Injection-site reactions (more common with TB-500 than BPC), WADA status — both are prohibited for tested athletes.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.